Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last ¥3,690 JPY
Change Today +50.00 / 1.37%
Volume 1.2M
As of 12:31 AM 10/5/15 All times are local (Market data is delayed by at least 15 minutes).

chugai pharmaceutical co ltd (4519) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/18/15 - ¥5,090
52 Week Low
01/7/15 - ¥2,862
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CHUGAI PHARMACEUTICAL CO LTD (4519)

Related News

No related news articles were found.

chugai pharmaceutical co ltd (4519) Related Businessweek News

No Related Businessweek News Found

chugai pharmaceutical co ltd (4519) Details

Chugai Pharmaceutical Co., Ltd. manufactures, sells, imports, and exports pharmaceutical products in Japan and internationally. Its products in oncology include Avastin, Herceptin, Rituxan, Xeloda, Tarceva, Neutrogin, Perjeta, Kadcyla, and Alecensa; bone and joint disease products comprise Actemra, Suvenyl, Edirol, Alfarol, and Bonviva; renal disease products consist of Mircera, Oxarol, and Epogin; and other products, such as Tamiflu, Sigmart, CellCept, Pegasys, and Copegus. The company has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, central nervous system, and other diseases. Chugai Pharmaceutical Co., Ltd. has a strategic alliance with Roche; co-development agreement with Taisho Pharmaceutical Co., Ltd.; and license agreement and collaboration with Athersys, Inc. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding AG.

7,023 Employees
Last Reported Date: 04/1/15
Founded in 1925

chugai pharmaceutical co ltd (4519) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: ¥266.0M
President, Chief Operating Officer and Repres...
Total Annual Compensation: ¥74.0M
Compensation as of Fiscal Year 2013.

chugai pharmaceutical co ltd (4519) Key Developments

Chugai Pharmaceutical Co. Ltd., Q2 2015 Earnings Call, Jul 24, 2015

Chugai Pharmaceutical Co. Ltd., Q2 2015 Earnings Call, Jul 24, 2015

Chugai Pharmaceutical Announces Relocation of Tokyo First Branch; Announces Management Changes

Chugai Pharmaceutical Co. Ltd. announced that it will be relocating its Tokyo First Branch as follows from its current location in Nishi-Shinjuku, Shinjuku- ku, Tokyo to Kita-Shinagawa, Shinagawa-ku, Tokyo in order to enhance the increased efficiency of activities under the territory of the branch. The Tokyo First Branch will occupy the entire 17th floor of "the Osaki Bright Core" office building, a 20-storey building with two floors underground that was completed in April of this year. The company announced the appointment of Mitsuru Kikuchi as senior vice president responsible for external affairs from senior vice president general manager of external affairs dept, Ryuuichi Kikuchi as associate vice president general manager of medical affairs Div. from associate vice president general manager of medical affairs Div. and department manager of medical science dept.; Naoya Fujihara as general manager of external affairs dept. from senior specialist of external affairs dept.; Tetsuro Orita as general manager of human capital development dept. from senior specialist of external affairs dept.; Kenji Karato as general manager of general affairs dept. from supervisory branch manager of tokyo branch 2; Atsushi Sato as General Manager of Corporate Social Responsibility Dept. from general manager of corporate social responsibility dept. and general manager of general affairs dept.

Chugai Pharmaceutical Co. Ltd. Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2015; Provides Dividend and Earnings Guidance for Year Ending December 31, 2015; Declares Dividend for the Second Quarter of 2015 Payable on September 1, 2015

Chugai Pharmaceutical Co. Ltd. reported unaudited consolidated earnings results for the six months ended June 30, 2015. For the period, the company's revenues were JPY 240,178 million compared to JPY 222,022 million a year ago. Operating profit was JPY 43,210 million compared to JPY 43,117 million a year ago. Profit before taxes was JPY 43,852 million compared to JPY 43,435 million a year ago. Net income attributable to the company shareholders was JPY 30,137 million compared to JPY 28,897 million a year ago. Diluted earnings per share was JPY 55.13 compared to JPY 52.95 a year ago. Total cash flows from operating activities was JPY 46,721 million compared to JPY 33,036 million a year ago. Purchase of property, plant and equipment was JPY 10,904 million compared to JPY 9,207 million a year ago. Purchase of intangible assets was JPY 2,878 million compared to JPY 1,267 million a year ago. Core revenues were JPY 222 billion compared to JPY 201 billion a year ago. Core operating profit JPY 45,882 million compared to JPY 85,000 million a year ago. Core earnings was JPY 58.3 per share compared to JPY 104.42 per share a year ago. Revenues for the second quarter under review were JPY 240.2 billion (an increase of 8.2% year on year) due to the strong growth in sales. For the second quarter, the company declared a dividend of JPY 26.00 per share compared to dividend of JPY 22 per share for the same period a year ago. Dividend payment to commence on September 1, 2015 For the year ending December 31, 2015, the company expects dividend of JPY 26.00 per share. For the year ending December 31, 2015, the company expects revenues of JPY 486,500 million, core operating profit of JPY 85,000 million, core earnings per share of JPY 104.42.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4519:JP ¥3,690.00 JPY +50.00

4519 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $55.82 USD +0.69
Eli Lilly & Co $87.52 USD +2.34
Merck KGaA €77.45 EUR -0.202
Sanofi €84.98 EUR +0.37
Teva Pharmaceutical Industries Ltd $60.06 USD +1.56
View Industry Companies

Industry Analysis


Industry Average

Valuation 4519 Industry Range
Price/Earnings 38.9x
Price/Sales 4.2x
Price/Book 3.3x
Price/Cash Flow 39.9x
TEV/Sales 3.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHUGAI PHARMACEUTICAL CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at